
By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
latest_posts
- 1
Computerized Moderation: Tracking down Equilibrium in the Advanced Age - 2
Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing - 3
Well informed: How to Take full advantage of Your Gadgets - 4
What’s your chronotype? Knowing whether you’re a night owl or an early bird could help you do better on tests and avoid scams - 5
Indoor Drinking Fountains: Famous Home Advancements during the Pandemic
Poll: 62% of Americans would oppose U.S. military action in Greenland
How a niche Catholic approach to infertility treatment became a new talking point for MAHA conservatives
Figure out How to Explore Your Direction to the Best Dental Embed Trained professional: A Far reaching Manual
Osteoporosis, the silent disease, can shorten your life − here’s how to prevent fractures and keep bones healthy
Pick the Ideal Family Feline Variety for Your Home
Flash flooding causes highways to close to and from Eilat
25 of the world’s best sandwiches
Pick Your Favored method of transportation
Pilot captures jaw-dropping northern lights show from 36,000 feet (photos)













